Monthly plasmapheresis for systemic lupus erythematosus with diffuse proliferative glomerulonephritis: a pilot study

Area of Science:

• Nephrology
• Immunology
• Rheumatology

Background:

• Systemic lupus erythematosus (SLE) can cause diffuse proliferative glomerulonephritis, a severe kidney disease.
• Conventional therapy for lupus nephritis has limitations in preserving renal function.

Purpose of the Study:

• To evaluate the efficacy of monthly plasma exchange as an adjunct to conventional therapy in patients with lupus nephritis.
• To assess the impact of plasmapheresis on renal function, disease activity, and treatment requirements.

Main Methods:

• A randomized controlled trial involving twelve patients with biopsy-proven diffuse proliferative glomerulonephritis secondary to SLE.
• Patients were assigned to either a control group (conventional therapy) or a plasmapheresis group (conventional therapy plus monthly 4-L plasma exchange).

Main Results:

• Patients receiving plasmapheresis demonstrated better preservation of kidney function compared to the control group.
• The plasmapheresis group experienced reduced disease activity, fewer hospitalizations, and decreased need for steroid and immunosuppressive medications.
• Immunologic activity was reduced in the plasmapheresis group, with no reported side effects from the procedure.

Conclusions:

• Monthly plasma exchange appears to be a safe and effective adjunctive therapy for lupus nephritis.
• Further randomized controlled trials are warranted to confirm these findings and establish plasmapheresis as a standard treatment option.